Home Healthcare Pharmaceuticals Radiotheranostics Market

Radiotheranostics Market Size, Share & Trends Analysis Report By Radioisotope (Iodine-131, Iodine-123, Gallium-68, Lutetium-177, 18F with Y-90, Others), By Approach (Targeted Therapeutic, Targeted Diagnostic), By Application (Oncology, Thyroid Cancer, Neuroendocrine Tumor, Hepatocellular Carcinoma, Prostate Cancer, Others) and By Country (U.S., Canada) Forecasts, 2026-2034

Last Updated: July 13, 2026 | Author: Dhanashri B | Format:
Overview TOC Segmentation Methodology
Download Free Sample

Market Segmentation

  1. Radiotheranostics Market , By Radioisotope  2022-2034 (USD MILLION/ Units)
    1. Iodine-131
    2. Iodine-123
    3. Gallium-68
    4. Lutetium-177
    5. 18F with Y-90
    6. Others
  2. Radiotheranostics Market , By Approach  2022-2034 (USD MILLION/ Units)
    1. Targeted Therapeutic
    2. Targeted Diagnostic
  3. Radiotheranostics Market , By Application  2022-2034 (USD MILLION/ Units)
    1. Oncology
    2. Thyroid Cancer
    3. Neuroendocrine Tumor
    4. Hepatocellular Carcinoma
    5. Prostate Cancer
    6. Others
      1. Neurological Disorders
      2. Arthritis
      3. Others
  4. Regional Radiotheranostics Market
    1. North America
      1. North America Radiotheranostics Market By Radioisotope  2022-2034 (USD MILLION/ Units)
        1. Iodine-131
        2. Iodine-123
        3. Gallium-68
        4. Lutetium-177
        5. 18F with Y-90
        6. Others
      2. North America Radiotheranostics Market By Approach  2022-2034 (USD MILLION/ Units)
        1. Targeted Therapeutic
        2. Targeted Diagnostic
      3. North America Radiotheranostics Market By Application  2022-2034 (USD MILLION/ Units)
        1. Oncology
        2. Thyroid Cancer
        3. Neuroendocrine Tumor
        4. Hepatocellular Carcinoma
        5. Prostate Cancer
        6. Others
          1. Neurological Disorders
          2. Arthritis
          3. Others
      4. U.S.
        1. Iodine-131
        2. Iodine-123
        3. Gallium-68
        4. Lutetium-177
        5. 18F with Y-90
        6. Others
        7. Targeted Therapeutic
        8. Targeted Diagnostic
        9. Oncology
        10. Thyroid Cancer
        11. Neuroendocrine Tumor
        12. Hepatocellular Carcinoma
        13. Prostate Cancer
        14. Others
          1. Neurological Disorders
          2. Arthritis
          3. Others
      5. Canada
        1. Iodine-131
        2. Iodine-123
        3. Gallium-68
        4. Lutetium-177
        5. 18F with Y-90
        6. Others
        7. Targeted Therapeutic
        8. Targeted Diagnostic
        9. Oncology
        10. Thyroid Cancer
        11. Neuroendocrine Tumor
        12. Hepatocellular Carcinoma
        13. Prostate Cancer
        14. Others
          1. Neurological Disorders
          2. Arthritis
          3. Others
    2. Europe
      1. Europe Radiotheranostics Market By Radioisotope  2022-2034 (USD MILLION/ Units)
        1. Iodine-131
        2. Iodine-123
        3. Gallium-68
        4. Lutetium-177
        5. 18F with Y-90
        6. Others
      2. Europe Radiotheranostics Market By Approach  2022-2034 (USD MILLION/ Units)
        1. Targeted Therapeutic
        2. Targeted Diagnostic
      3. Europe Radiotheranostics Market By Application  2022-2034 (USD MILLION/ Units)
        1. Oncology
        2. Thyroid Cancer
        3. Neuroendocrine Tumor
        4. Hepatocellular Carcinoma
        5. Prostate Cancer
        6. Others
          1. Neurological Disorders
          2. Arthritis
          3. Others
      4. U.K.
        1. Iodine-131
        2. Iodine-123
        3. Gallium-68
        4. Lutetium-177
        5. 18F with Y-90
        6. Others
        7. Targeted Therapeutic
        8. Targeted Diagnostic
        9. Oncology
        10. Thyroid Cancer
        11. Neuroendocrine Tumor
        12. Hepatocellular Carcinoma
        13. Prostate Cancer
        14. Others
          1. Neurological Disorders
          2. Arthritis
          3. Others
      5. Germany
        1. Iodine-131
        2. Iodine-123
        3. Gallium-68
        4. Lutetium-177
        5. 18F with Y-90
        6. Others
        7. Targeted Therapeutic
        8. Targeted Diagnostic
        9. Oncology
        10. Thyroid Cancer
        11. Neuroendocrine Tumor
        12. Hepatocellular Carcinoma
        13. Prostate Cancer
        14. Others
          1. Neurological Disorders
          2. Arthritis
          3. Others
      6. France
        1. Iodine-131
        2. Iodine-123
        3. Gallium-68
        4. Lutetium-177
        5. 18F with Y-90
        6. Others
        7. Targeted Therapeutic
        8. Targeted Diagnostic
        9. Oncology
        10. Thyroid Cancer
        11. Neuroendocrine Tumor
        12. Hepatocellular Carcinoma
        13. Prostate Cancer
        14. Others
          1. Neurological Disorders
          2. Arthritis
          3. Others
      7. Spain
        1. Iodine-131
        2. Iodine-123
        3. Gallium-68
        4. Lutetium-177
        5. 18F with Y-90
        6. Others
        7. Targeted Therapeutic
        8. Targeted Diagnostic
        9. Oncology
        10. Thyroid Cancer
        11. Neuroendocrine Tumor
        12. Hepatocellular Carcinoma
        13. Prostate Cancer
        14. Others
          1. Neurological Disorders
          2. Arthritis
          3. Others
      8. Italy
        1. Iodine-131
        2. Iodine-123
        3. Gallium-68
        4. Lutetium-177
        5. 18F with Y-90
        6. Others
        7. Targeted Therapeutic
        8. Targeted Diagnostic
        9. Oncology
        10. Thyroid Cancer
        11. Neuroendocrine Tumor
        12. Hepatocellular Carcinoma
        13. Prostate Cancer
        14. Others
          1. Neurological Disorders
          2. Arthritis
          3. Others
      9. Russia
        1. Iodine-131
        2. Iodine-123
        3. Gallium-68
        4. Lutetium-177
        5. 18F with Y-90
        6. Others
        7. Targeted Therapeutic
        8. Targeted Diagnostic
        9. Oncology
        10. Thyroid Cancer
        11. Neuroendocrine Tumor
        12. Hepatocellular Carcinoma
        13. Prostate Cancer
        14. Others
          1. Neurological Disorders
          2. Arthritis
          3. Others
      10. Nordic
        1. Iodine-131
        2. Iodine-123
        3. Gallium-68
        4. Lutetium-177
        5. 18F with Y-90
        6. Others
        7. Targeted Therapeutic
        8. Targeted Diagnostic
        9. Oncology
        10. Thyroid Cancer
        11. Neuroendocrine Tumor
        12. Hepatocellular Carcinoma
        13. Prostate Cancer
        14. Others
          1. Neurological Disorders
          2. Arthritis
          3. Others
      11. Benelux
        1. Iodine-131
        2. Iodine-123
        3. Gallium-68
        4. Lutetium-177
        5. 18F with Y-90
        6. Others
        7. Targeted Therapeutic
        8. Targeted Diagnostic
        9. Oncology
        10. Thyroid Cancer
        11. Neuroendocrine Tumor
        12. Hepatocellular Carcinoma
        13. Prostate Cancer
        14. Others
          1. Neurological Disorders
          2. Arthritis
          3. Others
      12. Rest of Europe
        1. Iodine-131
        2. Iodine-123
        3. Gallium-68
        4. Lutetium-177
        5. 18F with Y-90
        6. Others
        7. Targeted Therapeutic
        8. Targeted Diagnostic
        9. Oncology
        10. Thyroid Cancer
        11. Neuroendocrine Tumor
        12. Hepatocellular Carcinoma
        13. Prostate Cancer
        14. Others
          1. Neurological Disorders
          2. Arthritis
          3. Others
    3. APAC
      1. APAC Radiotheranostics Market By Radioisotope  2022-2034 (USD MILLION/ Units)
        1. Iodine-131
        2. Iodine-123
        3. Gallium-68
        4. Lutetium-177
        5. 18F with Y-90
        6. Others
      2. APAC Radiotheranostics Market By Approach  2022-2034 (USD MILLION/ Units)
        1. Targeted Therapeutic
        2. Targeted Diagnostic
      3. APAC Radiotheranostics Market By Application  2022-2034 (USD MILLION/ Units)
        1. Oncology
        2. Thyroid Cancer
        3. Neuroendocrine Tumor
        4. Hepatocellular Carcinoma
        5. Prostate Cancer
        6. Others
          1. Neurological Disorders
          2. Arthritis
          3. Others
      4. China
        1. Iodine-131
        2. Iodine-123
        3. Gallium-68
        4. Lutetium-177
        5. 18F with Y-90
        6. Others
        7. Targeted Therapeutic
        8. Targeted Diagnostic
        9. Oncology
        10. Thyroid Cancer
        11. Neuroendocrine Tumor
        12. Hepatocellular Carcinoma
        13. Prostate Cancer
        14. Others
          1. Neurological Disorders
          2. Arthritis
          3. Others
      5. Korea
        1. Iodine-131
        2. Iodine-123
        3. Gallium-68
        4. Lutetium-177
        5. 18F with Y-90
        6. Others
        7. Targeted Therapeutic
        8. Targeted Diagnostic
        9. Oncology
        10. Thyroid Cancer
        11. Neuroendocrine Tumor
        12. Hepatocellular Carcinoma
        13. Prostate Cancer
        14. Others
          1. Neurological Disorders
          2. Arthritis
          3. Others
      6. Japan
        1. Iodine-131
        2. Iodine-123
        3. Gallium-68
        4. Lutetium-177
        5. 18F with Y-90
        6. Others
        7. Targeted Therapeutic
        8. Targeted Diagnostic
        9. Oncology
        10. Thyroid Cancer
        11. Neuroendocrine Tumor
        12. Hepatocellular Carcinoma
        13. Prostate Cancer
        14. Others
          1. Neurological Disorders
          2. Arthritis
          3. Others
      7. India
        1. Iodine-131
        2. Iodine-123
        3. Gallium-68
        4. Lutetium-177
        5. 18F with Y-90
        6. Others
        7. Targeted Therapeutic
        8. Targeted Diagnostic
        9. Oncology
        10. Thyroid Cancer
        11. Neuroendocrine Tumor
        12. Hepatocellular Carcinoma
        13. Prostate Cancer
        14. Others
          1. Neurological Disorders
          2. Arthritis
          3. Others
      8. Australia
        1. Iodine-131
        2. Iodine-123
        3. Gallium-68
        4. Lutetium-177
        5. 18F with Y-90
        6. Others
        7. Targeted Therapeutic
        8. Targeted Diagnostic
        9. Oncology
        10. Thyroid Cancer
        11. Neuroendocrine Tumor
        12. Hepatocellular Carcinoma
        13. Prostate Cancer
        14. Others
          1. Neurological Disorders
          2. Arthritis
          3. Others
      9. Taiwan
        1. Iodine-131
        2. Iodine-123
        3. Gallium-68
        4. Lutetium-177
        5. 18F with Y-90
        6. Others
        7. Targeted Therapeutic
        8. Targeted Diagnostic
        9. Oncology
        10. Thyroid Cancer
        11. Neuroendocrine Tumor
        12. Hepatocellular Carcinoma
        13. Prostate Cancer
        14. Others
          1. Neurological Disorders
          2. Arthritis
          3. Others
      10. South East Asia
        1. Iodine-131
        2. Iodine-123
        3. Gallium-68
        4. Lutetium-177
        5. 18F with Y-90
        6. Others
        7. Targeted Therapeutic
        8. Targeted Diagnostic
        9. Oncology
        10. Thyroid Cancer
        11. Neuroendocrine Tumor
        12. Hepatocellular Carcinoma
        13. Prostate Cancer
        14. Others
          1. Neurological Disorders
          2. Arthritis
          3. Others
      11. Rest of Asia-Pacific
        1. Iodine-131
        2. Iodine-123
        3. Gallium-68
        4. Lutetium-177
        5. 18F with Y-90
        6. Others
        7. Targeted Therapeutic
        8. Targeted Diagnostic
        9. Oncology
        10. Thyroid Cancer
        11. Neuroendocrine Tumor
        12. Hepatocellular Carcinoma
        13. Prostate Cancer
        14. Others
          1. Neurological Disorders
          2. Arthritis
          3. Others
    4. Middle East and Africa
      1. Middle East and Africa Radiotheranostics Market By Radioisotope  2022-2034 (USD MILLION/ Units)
        1. Iodine-131
        2. Iodine-123
        3. Gallium-68
        4. Lutetium-177
        5. 18F with Y-90
        6. Others
      2. Middle East and Africa Radiotheranostics Market By Approach  2022-2034 (USD MILLION/ Units)
        1. Targeted Therapeutic
        2. Targeted Diagnostic
      3. Middle East and Africa Radiotheranostics Market By Application  2022-2034 (USD MILLION/ Units)
        1. Oncology
        2. Thyroid Cancer
        3. Neuroendocrine Tumor
        4. Hepatocellular Carcinoma
        5. Prostate Cancer
        6. Others
          1. Neurological Disorders
          2. Arthritis
          3. Others
      4. UAE
        1. Iodine-131
        2. Iodine-123
        3. Gallium-68
        4. Lutetium-177
        5. 18F with Y-90
        6. Others
        7. Targeted Therapeutic
        8. Targeted Diagnostic
        9. Oncology
        10. Thyroid Cancer
        11. Neuroendocrine Tumor
        12. Hepatocellular Carcinoma
        13. Prostate Cancer
        14. Others
          1. Neurological Disorders
          2. Arthritis
          3. Others
      5. Turkey
        1. Iodine-131
        2. Iodine-123
        3. Gallium-68
        4. Lutetium-177
        5. 18F with Y-90
        6. Others
        7. Targeted Therapeutic
        8. Targeted Diagnostic
        9. Oncology
        10. Thyroid Cancer
        11. Neuroendocrine Tumor
        12. Hepatocellular Carcinoma
        13. Prostate Cancer
        14. Others
          1. Neurological Disorders
          2. Arthritis
          3. Others
      6. Saudi Arabia
        1. Iodine-131
        2. Iodine-123
        3. Gallium-68
        4. Lutetium-177
        5. 18F with Y-90
        6. Others
        7. Targeted Therapeutic
        8. Targeted Diagnostic
        9. Oncology
        10. Thyroid Cancer
        11. Neuroendocrine Tumor
        12. Hepatocellular Carcinoma
        13. Prostate Cancer
        14. Others
          1. Neurological Disorders
          2. Arthritis
          3. Others
      7. South Africa
        1. Iodine-131
        2. Iodine-123
        3. Gallium-68
        4. Lutetium-177
        5. 18F with Y-90
        6. Others
        7. Targeted Therapeutic
        8. Targeted Diagnostic
        9. Oncology
        10. Thyroid Cancer
        11. Neuroendocrine Tumor
        12. Hepatocellular Carcinoma
        13. Prostate Cancer
        14. Others
          1. Neurological Disorders
          2. Arthritis
          3. Others
      8. Egypt
        1. Iodine-131
        2. Iodine-123
        3. Gallium-68
        4. Lutetium-177
        5. 18F with Y-90
        6. Others
        7. Targeted Therapeutic
        8. Targeted Diagnostic
        9. Oncology
        10. Thyroid Cancer
        11. Neuroendocrine Tumor
        12. Hepatocellular Carcinoma
        13. Prostate Cancer
        14. Others
          1. Neurological Disorders
          2. Arthritis
          3. Others
      9. Nigeria
        1. Iodine-131
        2. Iodine-123
        3. Gallium-68
        4. Lutetium-177
        5. 18F with Y-90
        6. Others
        7. Targeted Therapeutic
        8. Targeted Diagnostic
        9. Oncology
        10. Thyroid Cancer
        11. Neuroendocrine Tumor
        12. Hepatocellular Carcinoma
        13. Prostate Cancer
        14. Others
          1. Neurological Disorders
          2. Arthritis
          3. Others
      10. Rest of MEA
        1. Iodine-131
        2. Iodine-123
        3. Gallium-68
        4. Lutetium-177
        5. 18F with Y-90
        6. Others
        7. Targeted Therapeutic
        8. Targeted Diagnostic
        9. Oncology
        10. Thyroid Cancer
        11. Neuroendocrine Tumor
        12. Hepatocellular Carcinoma
        13. Prostate Cancer
        14. Others
          1. Neurological Disorders
          2. Arthritis
          3. Others
    5. LATAM
      1. LATAM Radiotheranostics Market By Radioisotope  2022-2034 (USD MILLION/ Units)
        1. Iodine-131
        2. Iodine-123
        3. Gallium-68
        4. Lutetium-177
        5. 18F with Y-90
        6. Others
      2. LATAM Radiotheranostics Market By Approach  2022-2034 (USD MILLION/ Units)
        1. Targeted Therapeutic
        2. Targeted Diagnostic
      3. LATAM Radiotheranostics Market By Application  2022-2034 (USD MILLION/ Units)
        1. Oncology
        2. Thyroid Cancer
        3. Neuroendocrine Tumor
        4. Hepatocellular Carcinoma
        5. Prostate Cancer
        6. Others
          1. Neurological Disorders
          2. Arthritis
          3. Others
      4. Brazil
        1. Iodine-131
        2. Iodine-123
        3. Gallium-68
        4. Lutetium-177
        5. 18F with Y-90
        6. Others
        7. Targeted Therapeutic
        8. Targeted Diagnostic
        9. Oncology
        10. Thyroid Cancer
        11. Neuroendocrine Tumor
        12. Hepatocellular Carcinoma
        13. Prostate Cancer
        14. Others
          1. Neurological Disorders
          2. Arthritis
          3. Others
      5. Mexico
        1. Iodine-131
        2. Iodine-123
        3. Gallium-68
        4. Lutetium-177
        5. 18F with Y-90
        6. Others
        7. Targeted Therapeutic
        8. Targeted Diagnostic
        9. Oncology
        10. Thyroid Cancer
        11. Neuroendocrine Tumor
        12. Hepatocellular Carcinoma
        13. Prostate Cancer
        14. Others
          1. Neurological Disorders
          2. Arthritis
          3. Others
      6. Argentina
        1. Iodine-131
        2. Iodine-123
        3. Gallium-68
        4. Lutetium-177
        5. 18F with Y-90
        6. Others
        7. Targeted Therapeutic
        8. Targeted Diagnostic
        9. Oncology
        10. Thyroid Cancer
        11. Neuroendocrine Tumor
        12. Hepatocellular Carcinoma
        13. Prostate Cancer
        14. Others
          1. Neurological Disorders
          2. Arthritis
          3. Others
      7. Chile
        1. Iodine-131
        2. Iodine-123
        3. Gallium-68
        4. Lutetium-177
        5. 18F with Y-90
        6. Others
        7. Targeted Therapeutic
        8. Targeted Diagnostic
        9. Oncology
        10. Thyroid Cancer
        11. Neuroendocrine Tumor
        12. Hepatocellular Carcinoma
        13. Prostate Cancer
        14. Others
          1. Neurological Disorders
          2. Arthritis
          3. Others
      8. Colombia
        1. Iodine-131
        2. Iodine-123
        3. Gallium-68
        4. Lutetium-177
        5. 18F with Y-90
        6. Others
        7. Targeted Therapeutic
        8. Targeted Diagnostic
        9. Oncology
        10. Thyroid Cancer
        11. Neuroendocrine Tumor
        12. Hepatocellular Carcinoma
        13. Prostate Cancer
        14. Others
          1. Neurological Disorders
          2. Arthritis
          3. Others
      9. Rest of LATAM
        1. Iodine-131
        2. Iodine-123
        3. Gallium-68
        4. Lutetium-177
        5. 18F with Y-90
        6. Others
        7. Targeted Therapeutic
        8. Targeted Diagnostic
        9. Oncology
        10. Thyroid Cancer
        11. Neuroendocrine Tumor
        12. Hepatocellular Carcinoma
        13. Prostate Cancer
        14. Others
          1. Neurological Disorders
          2. Arthritis
          3. Others
Report Details
−
200+ Trusted Partners
LG Electronics AMCAD Engineering KOBE STEEL LTD. Hindustan National Glass & Industries Limited Voith Group International Paper Hansol Paper Whirlpool Corporation Sony Samsung Electronics Qualcomm Google Fiserv Veto-Pharma Nippon Becton Dickinson Merck Argon Medical Devices Abbott Ajinomoto Denon Doosan Meiji Seika Kaisha Ltd LG Chemicals LCY chemical group Bayer Airrane BASF Toyota Industries Nissan Motors Neenah Mitsubishi Hyundai Motor Company Honda CRP Industries Inc pewag LGE Panasonic Lubrizol Corporation Leonardo Johnson & Johnson HB Fuller MITSUBISHI CHEMICAL Hyundai Mobis Amazon
Download Free Sample
Reach out to us
+1 646 905 0080 (U.S.)
+44 203 695 0070 (U.K.)
sales@straitsresearch.com

We are featured on:

Straits Research
Address:
105, Panchshil The Golden Bell,
Koregaon Park Annexe, Mundhwa,
Pune, Maharashtra 411036
Contact Us:
+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)

sales@straitsresearch.com

Quick Links
Help
Verified. Protected. Secure.
Duns
DMCA.com Protection Status
lets-encrypt
Secure Payments:
Secure Payments
Follow Us:
www.straitsresearch.com © Copyright . All rights Reserved.